Efficacy and Safety of MK-1942 When Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression (TRD) (MK-1942-006)

Phase 2 Terminated 99 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The main purpose of this study is to assess the efficacy and safety of daily and intermittent dosing of MK-1942 compared to placebo among participants with Treatment-Resistant Depression (TRD) on a stable course of antidepressant therapy. The dual primary hypotheses of the study are that the daily MK-1942 treatment or intermittent MK-1942 treatment are superior to placebo in reducing Montgomery-Asberg Depression Rating Scale (MADRS) score.

Timeline

Start: 2021-05-20
Primary completion: 2023-09-08
Completion: 2023-09-08

Publications

Results Merola A, Mukai Y, Bueters T, Ceesay P, Dupre N, Furtek C, Sanacora G, Thase ME, Targum SD, Smith SM, Egan MF. Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression. J Clin Psychopharmacol. 2026 Jul-Aug 01;46(4):427-432. doi: 10.1097/JCP.0000000000002171. Epub 2026 Mar 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MK-1942	Unknown	10 mg	Oral
Subject	MK-1942	Unknown	20 mg	Oral

Indications

No indication recorded.